Amgen's most recent trend suggests a bullish bias. One trading opportunity on Amgen is a Bull Put Spread using a strike $170.00 short put and a strike $160.00 long put offers a potential 7.76% return on risk over the next 27 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $170.00 by expiration. The full premium credit of $0.72 would be kept by the premium seller. The risk of $9.28 would be incurred if the stock dropped below the $160.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Amgen is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Amgen is bullish.
The RSI indicator is at 75.47 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Amgen
FDA Accepts Biologics License Application For Aimovig™ (erenumab)
Thu, 20 Jul 2017 20:30:00 +0000
THOUSAND OAKS, Calif., July 20, 2017 /PRNewswire/ — Amgen (AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for Aimovig™ (erenumab) for the prevention of migraine in patients experiencing four or more migraine days per month. If approved, Aimovig is expected to be the first-and-only monoclonal antibody targeting the calcitonin gene-related peptide (CGRP) receptor, specifically designed for the prevention of migraine.
Amgen Announces Webcast of 2017 Second Quarter Financial Results
Thu, 20 Jul 2017 20:00:00 +0000
THOUSAND OAKS, Calif., July 20, 2017 /PRNewswire/ — Amgen (AMGN) today announced that it will report its second quarter financial results on Tuesday, July 25, 2017, after the close of the U.S. financial markets. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team. The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com, under Investors.
Biotech Stocks On Verge Of Next Major Move Up
Wed, 19 Jul 2017 18:30:00 +0000
A biotech breakout may be fueled by positive medical data and earnings
Biotech Stock Roundup: Vertex Boosted by CF Data, FDA Nod for Gilead, Puma Drugs
Wed, 19 Jul 2017 12:39:12 +0000
Vertex (VRTX) got a significant boost with positive data from its cystic fibrosis (CF) pipeline while quite a few companies provided regulatory updates.
3 Dividend Stocks That Thrive in Both Bull and Bear Markets
Wed, 19 Jul 2017 12:04:00 +0000
Whether the stock market's up or down, Enterprise Product Partners, Automatic Data Processing, and Amgen should keep the dividends flowing.
Related Posts
Also on Market Tamer…
Follow Us on Facebook